Targeting EGFR and PI3K pathways in ovarian cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) is present in ovarian cancer but single-agent therapies show limited efficacy.
• Alternative pathways, such as the PI3K/Akt/MTOR pathway, may contribute to treatment resistance.
• Investigating combined inhibition of EGFR and PI3K pathways is crucial for improving ovarian cancer treatment.

Purpose of the Study:

• To evaluate the efficacy of combining PI3K inhibitors (ZSTK474, sirolimus) with EGFR inhibitors (erlotinib, gefitinib) in ovarian cancer.
• To explore potential synergistic effects and identify biomarkers predictive of response.

Main Methods:

• Primary ovarian cancer cell cultures were treated with single agents and drug combinations.
• Assays were performed to assess drug activity, synergy, and potential resistance mechanisms.
• Tumor molecular profiling (e.g., PIK3CA, PTEN, KRAS) was conducted.

Main Results:

• Single-agent EGFR inhibitors had minimal activity; ZSTK474 showed some single-agent activity.
• Combinations of ZSTK474 with EGFR inhibitors demonstrated enhanced activity and synergy.
• Sirolimus combinations were less effective. EGFR expression correlated with sensitivity to EGFR inhibitors and resistance to PI3K agents.

Conclusions:

• Combined inhibition of EGFR and PI3K pathways shows therapeutic potential in ovarian cancer.
• Further clinical trials (Phase I/II) are warranted with detailed pharmacodynamic and molecular analyses.
• Identifying predictive biomarkers is essential for patient stratification and optimizing treatment strategies.